1. Home
  2. KOPN vs ENTX Comparison

KOPN vs ENTX Comparison

Compare KOPN & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

N/A

Current Price

$4.82

Market Cap

396.8M

Sector

Technology

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$3.00

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KOPN
ENTX
Founded
1984
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.8M
147.4M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
KOPN
ENTX
Price
$4.82
$3.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$4.69
$9.00
AVG Volume (30 Days)
3.0M
358.0K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
103.03
N/A
EPS
N/A
0.22
Revenue
$1,530,311.00
$42,000.00
Revenue This Year
$50.07
N/A
Revenue Next Year
$33.33
N/A
P/E Ratio
N/A
$13.77
Revenue Growth
46.53
N/A
52 Week Low
$1.81
$0.91
52 Week High
$6.61
$4.20

Technical Indicators

Market Signals
Indicator
KOPN
ENTX
Relative Strength Index (RSI) 55.48 56.06
Support Level $4.56 $2.73
Resistance Level $5.53 $3.10
Average True Range (ATR) 0.25 0.18
MACD -0.01 -0.03
Stochastic Oscillator 78.31 74.47

Price Performance

Historical Comparison
KOPN
ENTX

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: